<code id='D325D07EE7'></code><style id='D325D07EE7'></style>
    • <acronym id='D325D07EE7'></acronym>
      <center id='D325D07EE7'><center id='D325D07EE7'><tfoot id='D325D07EE7'></tfoot></center><abbr id='D325D07EE7'><dir id='D325D07EE7'><tfoot id='D325D07EE7'></tfoot><noframes id='D325D07EE7'>

    • <optgroup id='D325D07EE7'><strike id='D325D07EE7'><sup id='D325D07EE7'></sup></strike><code id='D325D07EE7'></code></optgroup>
        1. <b id='D325D07EE7'><label id='D325D07EE7'><select id='D325D07EE7'><dt id='D325D07EE7'><span id='D325D07EE7'></span></dt></select></label></b><u id='D325D07EE7'></u>
          <i id='D325D07EE7'><strike id='D325D07EE7'><tt id='D325D07EE7'><pre id='D325D07EE7'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:9
          Courtesy Sanofi

          LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

          The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.   

          advertisement

          Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Antibody drugs appear effective. Now can we make enough of them?
          Antibody drugs appear effective. Now can we make enough of them?

          VincenzoRusso,aresearcheratRegeneron,workstoisolateviralDNAclonesofSARS-CoV-2.EricaYoonforSTATTheCov

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Readout Newsletter: Beam, Prozac, "TechBio" and more

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo